Qdata Anti-VEGF Market Tracker

Qdata Anti-VEGF Market Tracker, developed by Verana Health, tracks real-world usage of anti-VEGF (vascular endothelial growth factor) therapies in patients with retinal conditions, with granularity down to the brand level. The tool is designed for life sciences commercialization teams that need accurate, timely market data to support commercial planning and market forecasting in the ophthalmology space.

Anti-VEGF treatments are intravitreal injections administered by ophthalmologists to counteract excess VEGF protein production in the eye, which can cause abnormal blood vessel growth leading to vision damage or loss. The tracker covers patients treated for conditions including age-related macular degeneration, diabetic retinopathy, and other ophthalmic conditions. Verana Health operates as an exclusive analytics and real-world data curation partner with the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), which serves as the underlying clinical data source.

Key Data Capabilities

• Tracks real-world anti-VEGF usage at the brand level across patient populations with retinal conditions
• Supports monitoring of rolling market share, brand usage, and brand switching by indication
• Curated EHR data can be segmented by brand, geography, demographics, and additional variables
• Data is refreshed monthly with an approximately three-week data lag, sourced consistently from the same clinical systems
• Exclusive access to insights derived from the IRIS® Registry, not available through other sources

Market Dashboard Features

• Self-service dashboards designed for day-to-day commercial use
• Tracks rolling market share and user-defined key performance indicators
• Monitors real-world drug usage including brand switching and brand usage by indication
• Flexible access options: dashboards for direct use, or raw data delivery via SFTP or AWS Data Exchange

Scale of the Dataset

• Covers millions of de-identified patients who have received anti-VEGF injections (data as of July 2025)
• Encompasses millions of recorded anti-VEGF injections
• Draws from contributions by a large number of clinicians
• Data counts for research purposes are dependent on project scope, feasibility, and integration status

The tracker is available to life sciences teams seeking on-demand access to anti-VEGF real-world data. Data delivery is supported through flexible integration options including SFTP and AWS Data Exchange, and Verana Health offers direct consultation with Qdata experts to discuss data counts, feasibility, and project scope.